Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 34 studies | 26% ± 8% | |
macrophage | 23 studies | 28% ± 10% | |
fibroblast | 19 studies | 25% ± 9% | |
microglial cell | 10 studies | 26% ± 9% | |
astrocyte | 10 studies | 30% ± 13% | |
monocyte | 9 studies | 29% ± 19% | |
glutamatergic neuron | 9 studies | 45% ± 24% | |
oligodendrocyte precursor cell | 9 studies | 29% ± 12% | |
endothelial cell of vascular tree | 9 studies | 25% ± 11% | |
myeloid cell | 8 studies | 33% ± 10% | |
adipocyte | 8 studies | 31% ± 7% | |
oligodendrocyte | 8 studies | 25% ± 8% | |
endothelial cell of artery | 7 studies | 26% ± 7% | |
GABAergic neuron | 7 studies | 42% ± 20% | |
interneuron | 6 studies | 40% ± 24% | |
pericyte | 6 studies | 24% ± 5% | |
retinal cone cell | 6 studies | 30% ± 9% | |
dendritic cell | 6 studies | 21% ± 3% | |
vein endothelial cell | 6 studies | 27% ± 13% | |
endothelial cell of lymphatic vessel | 6 studies | 27% ± 9% | |
neuron | 5 studies | 30% ± 11% | |
epithelial cell | 5 studies | 29% ± 6% | |
conventional dendritic cell | 5 studies | 22% ± 9% | |
smooth muscle cell | 5 studies | 22% ± 3% | |
type I pneumocyte | 5 studies | 20% ± 5% | |
type II pneumocyte | 5 studies | 19% ± 5% | |
mononuclear phagocyte | 4 studies | 24% ± 10% | |
granule cell | 4 studies | 28% ± 10% | |
ciliated cell | 4 studies | 19% ± 3% | |
connective tissue cell | 4 studies | 23% ± 5% | |
GABAergic interneuron | 3 studies | 23% ± 5% | |
mesothelial cell | 3 studies | 19% ± 3% | |
retinal rod cell | 3 studies | 22% ± 4% | |
abnormal cell | 3 studies | 33% ± 17% | |
capillary endothelial cell | 3 studies | 22% ± 2% | |
hepatocyte | 3 studies | 35% ± 22% | |
ependymal cell | 3 studies | 25% ± 12% | |
adventitial cell | 3 studies | 23% ± 4% | |
alveolar macrophage | 3 studies | 34% ± 8% | |
club cell | 3 studies | 20% ± 6% | |
Schwann cell | 3 studies | 46% ± 17% | |
lymphocyte | 3 studies | 18% ± 0% | |
melanocyte | 3 studies | 30% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 3115.92 | 459 / 459 | 100% | 13.59 | 1117 / 1118 |
skin | 100% | 4290.19 | 1809 / 1809 | 99% | 28.55 | 469 / 472 |
prostate | 100% | 2005.98 | 244 / 245 | 99% | 6.45 | 499 / 502 |
lung | 100% | 3064.35 | 577 / 578 | 99% | 9.20 | 1144 / 1155 |
esophagus | 99% | 1683.41 | 1436 / 1445 | 99% | 13.22 | 182 / 183 |
brain | 99% | 2286.74 | 2627 / 2642 | 99% | 10.98 | 700 / 705 |
uterus | 100% | 2016.73 | 170 / 170 | 99% | 7.35 | 453 / 459 |
pancreas | 100% | 1465.01 | 328 / 328 | 98% | 9.20 | 175 / 178 |
thymus | 100% | 2215.51 | 652 / 653 | 98% | 6.29 | 595 / 605 |
stomach | 100% | 1674.84 | 358 / 359 | 98% | 7.23 | 279 / 286 |
intestine | 100% | 2149.11 | 966 / 966 | 96% | 5.90 | 506 / 527 |
bladder | 100% | 2302.48 | 21 / 21 | 96% | 6.34 | 482 / 504 |
ovary | 100% | 1662.70 | 180 / 180 | 95% | 5.05 | 408 / 430 |
kidney | 100% | 1426.82 | 89 / 89 | 93% | 8.73 | 842 / 901 |
adrenal gland | 100% | 1619.99 | 258 / 258 | 91% | 6.15 | 209 / 230 |
liver | 93% | 753.49 | 211 / 226 | 80% | 3.95 | 324 / 406 |
adipose | 100% | 4253.49 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 4.82 | 29 / 29 |
spleen | 100% | 1384.57 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.28 | 1 / 1 |
blood vessel | 100% | 2478.56 | 1334 / 1335 | 0% | 0 | 0 / 0 |
muscle | 98% | 992.84 | 790 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 95% | 9.35 | 76 / 80 |
heart | 93% | 1229.26 | 805 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 93% | 6.72 | 42 / 45 |
peripheral blood | 63% | 546.20 | 585 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0071300 | Biological process | cellular response to retinoic acid |
GO_0032956 | Biological process | regulation of actin cytoskeleton organization |
GO_0035024 | Biological process | negative regulation of Rho protein signal transduction |
GO_0035640 | Biological process | exploration behavior |
GO_0010976 | Biological process | positive regulation of neuron projection development |
GO_0007165 | Biological process | signal transduction |
GO_1903905 | Biological process | positive regulation of establishment of T cell polarity |
GO_0007155 | Biological process | cell adhesion |
GO_0051353 | Biological process | positive regulation of oxidoreductase activity |
GO_0018108 | Biological process | peptidyl-tyrosine phosphorylation |
GO_0007204 | Biological process | positive regulation of cytosolic calcium ion concentration |
GO_0010506 | Biological process | regulation of autophagy |
GO_0036211 | Biological process | protein modification process |
GO_2000145 | Biological process | regulation of cell motility |
GO_0030100 | Biological process | regulation of endocytosis |
GO_0007173 | Biological process | epidermal growth factor receptor signaling pathway |
GO_0006468 | Biological process | protein phosphorylation |
GO_2000406 | Biological process | positive regulation of T cell migration |
GO_0030155 | Biological process | regulation of cell adhesion |
GO_0005886 | Cellular component | plasma membrane |
GO_0015629 | Cellular component | actin cytoskeleton |
GO_0005829 | Cellular component | cytosol |
GO_0004715 | Molecular function | non-membrane spanning protein tyrosine kinase activity |
GO_0003785 | Molecular function | actin monomer binding |
GO_0004713 | Molecular function | protein tyrosine kinase activity |
GO_0051015 | Molecular function | actin filament binding |
GO_0000287 | Molecular function | magnesium ion binding |
GO_0004672 | Molecular function | protein kinase activity |
GO_0030145 | Molecular function | manganese ion binding |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
GO_0001784 | Molecular function | phosphotyrosine residue binding |
Gene name | ABL2 |
Protein name | Tyrosine-protein kinase ABL2 (EC 2.7.10.2) (Abelson murine leukemia viral oncogene homolog 2) (Abelson tyrosine-protein kinase 2) (Abelson-related gene protein) (Tyrosine-protein kinase ARG) |
Synonyms | ARG ABLL |
Description | FUNCTION: Non-receptor tyrosine-protein kinase that plays an ABL1-overlapping role in key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion and receptor endocytosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like MYH10 (involved in movement); CTTN (involved in signaling); or TUBA1 and TUBB (microtubule subunits). Binds directly F-actin and regulates actin cytoskeletal structure through its F-actin-bundling activity. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as CRK, CRKL, DOK1 or ARHGAP35. Adhesion-dependent phosphorylation of ARHGAP35 promotes its association with RASA1, resulting in recruitment of ARHGAP35 to the cell periphery where it inhibits RHO. Phosphorylates multiple receptor tyrosine kinases like PDGFRB and other substrates which are involved in endocytosis regulation such as RIN1. In brain, may regulate neurotransmission by phosphorylating proteins at the synapse. ABL2 acts also as a regulator of multiple pathological signaling cascades during infection. Pathogens can highjack ABL2 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. Positively regulates chemokine-mediated T-cell migration, polarization, and homing to lymph nodes and immune-challenged tissues, potentially via activation of NEDD9/HEF1 and RAP1 (By similarity). . |
Accessions | P42684 ENST00000367623.8 [P42684-6] ENST00000504405.5 [P42684-4] ENST00000507173.5 [P42684-7] ENST00000502732.6 [P42684-1] ENST00000344730.8 [P42684-10] ENST00000512653.5 [P42684-3] ENST00000511413.5 [P42684-5] |